Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Henn Matthew R, holds the title of See Remarks at Seres Therapeutics, Inc..
On 2026-11-16, the insider transacted 339 shares.The shares were transacted at a weighted average price of $0.41 per share, resulting in a total market-relevant value of $139.38.
Henn Matthew R (See Remarks) sold $139 of $MCRB
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.